As a former Executive Director Research and Development at Endotis Pharma, Dr. Maurice Petitou has 32 years of experience in pharmaceutical industry (mainly at Sanofi group). He is one of the historical co-inventor of “Fraxiparine”, the first Low Molecular Weight Heparin (LMWH) marketed. Afterwards, he has developed a further generation of Utra Low Molecular Weight Heparin e.g. “Arixtra” (first synthetic sugar based drug). Two other new chemical entities (synthetic oligosaccharides) reached clinical trials (SR123781 Ph IIb, idrabiotaparinux Ph III)